NASDAQ$SANA
Sana Biotechnology Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Sana reported financial results and business highlights, advancing clinical programs and achieving IND clearance for autoimmune diseases and B-cell malignancies.
Sana Biotechnology reported a net loss of $88.1 million for Q4 2023, with cash, cash equivalents, and marketable securities totaling $205.2 million. The company is advancing four clinical programs and expects to treat 40-60 patients across multiple indications in 2024.
- Advanced four clinical programs across seven indications, including allogeneic CAR T programs and a primary islet cell therapy.
- SC291 IND cleared for B-cell mediated autoimmune diseases, with initial clinical data expected in 2024.
- SC262 IND cleared for relapsed/refractory B-cell malignancies, with initial clinical data expected in 2024.
- CTA authorized for investigator-sponsored trial with hypoimmune-modified primary islet cells; potential clinical data in 1H2024.
Headline financials
Revenue & EPS history
Sana · Revenue · Quarterly
$0
Forward guidance
Sana anticipates treating 40-60 patients in 2024 across multiple trials and indications, aiming to demonstrate successful allogeneic cell transplantation without immune detection or rejection.
Tailwinds
- Goal to treat 40-60 patients in 2024 in four trials across seven indications.
- Early SC291 data suggests ability to dose safely, demonstrate desired immune evasion profile, and early clinical efficacy.
- SC291 IND clearance for B-cell mediated autoimmune diseases with goal to report initial clinical data in 2024.
- SC262 IND clearance for relapsed/refractory B-cell malignancies with goal to report initial clinical data in 2024.
- Recent financing supports activities through multiple data readouts.
Headwinds
- Focusing investment on ex vivo platform and reducing investment in fusogen in vivo delivery platform.
- Decrease in cash position due to operating cash burn and purchase of property and equipment.
- Net loss for the quarter was $88.1 million.
- Research and development expenses include non-cash stock-based compensation.
- The value of potential liabilities may fluctuate significantly with changes in Sana’s market capitalization and stock price.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-1.2%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+4.1%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+22.3%
Q2 2022
Best reaction
-25.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.5% | -15.3% | -18.6% | |
| Q3 2025 | -0.2% | +3.9% | +25.7% | |
| Q2 2025 | +7.3% | +14.0% | +16.4% | |
| Q1 2025 | +0.6% | -1.7% | +56.9% | |
| Q4 2024 | -17.7% | -16.6% | -40.4% | |
| Q3 2024 | -6.8% | -14.2% | -25.8% | |
| Q1 2024 | -25.3% | -21.2% | -30.5% | |
| Q4 2023 | +5.6% | -8.1% | -6.3% | |
| Q3 2023 | -14.8% | -10.3% | -4.1% | |
| Q2 2023 | -3.8% | -1.3% | -4.5% | |
| Q1 2023 | +7.2% | +11.8% | +8.9% | |
| Q4 2022 | +2.3% | +2.3% | +51.8% | |
| Q3 2022 | -14.1% | -21.6% | -22.2% | |
| Q2 2022 | +22.3% | +18.3% | -3.0% | |
| Q1 2022 | -5.6% | -11.9% | -11.4% | |
| Q4 2021 | +21.1% | +19.5% | +45.6% | |
| Q3 2021 | -5.7% | -3.3% | -19.2% | |
| Q2 2020 | +10.2% | +9.5% | +40.5% | |
| Q2 2021 | +10.2% | +9.5% | +40.5% | |
| Q1 2021 | -13.1% | -1.9% | +9.9% | |
| Q4 2020 | -5.7% | -4.1% | -23.7% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro